We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Effect of SARS-CoV-2 BNT162b2 mRNA vaccine on thyroid autoimmunity: A twelve-month follow-up study.
- Authors
Shuhei Morita; Tomoyuki Takagi; Hidefumi Inaba; Yasushi Furukawa; Shohei Kishimoto; Shinsuke Uraki; Naoki Shimo; Ken Takeshima; Saya Uraki; Kei Doi; Mitsuyo Imagawa; Mika Kokawa; Tomomi Konami; Hitomi Hara; Yoshihiro Hara; Emiko Sone; Hiroto Furuta; Masahiro Nishi; Asako Doi; Shinobu Tamura
- Abstract
Objectives: Graves' disease (GD) has been highlighted as a possible adverse effect of the respiratory syndrome coronavirus-2 (SARS-CoV-2) vaccine. However, it is unknown if the SARS-CoV-2 vaccine disrupts thyroid autoimmunity. We aimed to present long-term follow-up of thyroid autoimmunity after the SARS-CoV-2 BNT162b2 mRNA vaccine. Methods: Serum samples collected from seventy Japanese healthcare workers at baseline, 32 weeks after the second dose (pre-third dose), and 4 weeks after the third dose of the vaccine were analyzed. The time courses of anti-SARS-CoV-2 spike immunoglobulin G (IgG) antibody, thyroid-stimulating hormone receptor antibody (TRAb), and thyroid function were evaluated. Anti-thyroglobulin antibodies (TgAb) and anti-thyroid peroxidase antibodies (TPOAb) were additionally evaluated in thirtythree participants. Results: The median agewas 50 (IQR, 38-54) years and 69% were female. The median anti-spike IgG antibody titer was 17627 (IQR, 10898-24175) U/mL 4 weeks after the third dose. The mean TRAb was significantly increased from 0.81 (SD, 0.05) IU/L at baseline to 0.97 (SD, 0.30) IU/L 4 weeks after the third dose without functional changes. An increase in TRAb was positively associated with female sex (β = 0.32, P = 0.008) and low basal FT4 (β = -0.29, P = 0.02) and FT3 (β = -0.33, P = 0.004). TgAb was increased by the third dose. Increase in TgAb was associated with history of the thyroid diseases (β = 0.55, P <0.001). Conclusions: SARS-CoV-2 BNT162b2 mRNA vaccine can disrupt thyroid autoimmunity. Clinicians should consider the possibility that the SARS-CoV-2 vaccine may disrupt thyroid autoimmunity.
- Subjects
MEDICAL personnel; COVID-19 vaccines; THYROID diseases; THYROID gland; SARS-CoV-2; AUTOIMMUNITY
- Publication
Frontiers in Endocrinology, 2023, Vol 14, p1
- ISSN
1664-2392
- Publication type
Article
- DOI
10.3389/fendo.2023.1058007